Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Ранг среди акций
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Цена акции
$4.48
Рыночная капитализация
$4.99B
Изменение (1 день)
-5.20%
Изменение (1 год)
-41.89%
Страна
CN
Торговля Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Категория
Healthcare
EPS для Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
EPS по состоянию на June 2026 TTM: $0.09
Согласно последним финансовым отчетам и цене акций Shenzhen Salubris Pharmaceuticals Co., Ltd., текущий EPS компании (TTM) составляет $0.09. В конце 2024 EPS компании составлял $0.07, равна показателю 2023 года, равному $0.07.
История EPS компании Shenzhen Salubris Pharmaceuticals Co., Ltd. с 2006 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2026 (TTM) | $0.09 | 12.25% |
| 2025 | $0.08 | 12.03% |
| 2024 | $0.07 | 0.68% |
| 2023 | $0.07 | -12.60% |
| 2022 | $0.08 | 6.86% |
| 2021 | $0.08 | 764.84% |
| 2020 | $0.01 | -90.82% |
| 2019 | $0.10 | -50.96% |
| 2018 | $0.20 | -5.38% |
| 2017 | $0.21 | 11.48% |
| 2016 | $0.19 | 2.84% |
| 2015 | $0.19 | 15.43% |
| 2014 | $0.16 | 23.96% |
| 2013 | $0.13 | 33.13% |
| 2012 | $0.10 | 58.00% |
| 2011 | $0.06 | 20.19% |
| 2010 | $0.05 | 40.71% |
| 2009 | $0.04 | 66.36% |
| 2008 | $0.02 | 71.88% |
| 2007 | $0.01 | 91.04% |
| 2006 | $0.01 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $8.37 | 9,220.71% |
US
|
|
| $6.41 | 7,032.74% |
FR
|
|
| - | - |
JP
|
|
| $3.32 | 3,597.10% |
US
|
|
| - | - |
CH
|
